Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immu...
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
About this item
Full title
Author / Creator
Yi, Ming , Niu, Mengke , Wu, Yuze , Ge, Hong , Jiao, Dechao , Zhu, Shuangli , Zhang, Jing , Yan, Yongxiang , Zhou, Pengfei , Chu, Qian and Wu, Kongming
Publisher
London: BioMed Central
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central
Subjects
More information
Scope and Contents
Contents
Background Non-inflamed tumors, including immune-excluded and immune-desert tumors, are commonly resistant to anti-PD-1/PD-L1 (α-PD-1/PD-L1) therapy. Our previous study reported the potent antitumor activity of anti-TGF-β/PD-L1 bispecific antibody YM101 in immune-excluded tumors. However, YM101 had limited antitumor activity in immune-desert models...
Alternative Titles
Full title
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_f2459977682746b29f14b3be67a8da61
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f2459977682746b29f14b3be67a8da61
Other Identifiers
ISSN
1756-8722
E-ISSN
1756-8722
DOI
10.1186/s13045-022-01363-8
